Nachrichten zur Teva Pharmaceutical Industries Ltd. ADR Aktie

TEVA Pharmaceutical: Jefferies erhöht Rating und Kursziel - Aktienanalyse

New York (www.aktiencheck.de) - TEVA Pharmaceutical-Aktienanalyse von Jefferies & Co: Glen Santangelo, Analyst von Jefferies & Co, stuft die ADR-Aktie von…

Global Transplantation Market Size To Exceed USD 21.2 Billion By 2032 | CAGR of 9.5%

The Global Transplantation Market Size was valued at USD 8.5 Billion in 2022 and the Worldwide Transplantation Market Size is…

TEVA Pharmaceutical: BofA erhöht das Kursziel und rät zum Kauf - Aktienanalyse

Charlotte (www.aktiencheck.de) - TEVA Pharmaceutical-Aktienanalyse von BofA Securities: Jason Gerberry, Analyst von BofA Securities, stuft die Aktie von TEVA Pharmaceutical Industries…

Calibre Scientific Acquires MoBiTec, a German Supplier of Research Tools for the Global Life Science, Diagnostic, and Pharmaceutical Industries

LOS ANGELES, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of MoBiTec GmbH (“MoBiTec”…

Teva once again most valuable company on TASE

After just over a year in the job, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) CEO Richard Francis…

Teva ends 2023 as Israeli co with biggest profit on Wall Street

Israel’s most profitable company on Wall Street in 2023 is somewhat surprising. Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE:…

Teva buys rights for Israeli co Biolojic’s asthma treatment

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Israeli company Biolojic Design have signed a collaboration agreement. Teva…

Multiple Myeloma Market revenue to surpass USD 71 Billion by 2035, says Research Nester

Major multiple myeloma market players include Amgen Inc., Johnson & Johnson, Takeda Pharmaceuticals Company Limited, Novartis AG, Sanofi, Teva Pharmaceuticals…

Subdermal Contraceptive Implants Market revenue to reach USD 3 Billion by 2036, says Research Nester

Major subdermal contraceptive implants market players include Merck & Co., Inc., Shanghai Dahua Pharmaceutical Co., Ltd, Bayer AG, Wyeth Pharmaceuticals,…

UBS upgrades Teva due to “attractive brand assets”

Swiss bank UBS has upgraded its recommendation for Israeli drugmaker Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) to…

Global Sleep Apnea Oral Appliances Market Size Worth USD 1.55 Billion By 2032 | CAGR of 13.2%

The Global Sleep Apnea Oral Appliances Market Size was valued at USD 0.45 Billion in 2022 and the Worldwide Sleep…

Teva Pharmaceutical analysts boost target price as brand transition underway

Teva Pharmaceutical Industries (NASDAQ:TEVA) Ltd is uniquely positioned to undergo a significant transition to a more brand focused company that…

Global Glaucoma Treatment Market Size To Grow USD 10.5 Billion by 2032 | CAGR of 5.0%

The Global Glaucoma Treatment Market Size was valued at USD 6.4 Billion in 2022 and the Worldwide Glaucoma Treatment Market…

Teva signs $125m deal with Royalty Pharma on antipsychotic drug

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to…

Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript

TEVA earnings call for the period ending September 30, 2023.…

Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript

…

Teva Pharmaceuticals says production largely unaffected by Israel-Hamas conflict, raises guidance

Teva Pharmaceutical Industries (NASDAQ:TEVA), one of Israels largest companies and a global leader in generic medicine production, said Wednesday that…

Teva Pharmaceuticals says production is largely unaffected from Israel-Hamas conflict, raises guidance

Teva Pharmaceutical Industries (NASDAQ:TEVA), one of Israels largest companies and a global leader in generic medicine production, said Wednesday that…

Krieg in Israel: Deutsche Firmen warten mit Investitionen ab

BERLIN (dpa-AFX) - Deutsche Mittelständler reagieren mit Vorsicht auf den Krieg in Israel. "Einige Unternehmen fahren…

Active Pharmaceutical Ingredients (API) Market Size to Surpass USD 349.2 Billion Growth by 2030, Exhibit a CAGR of 6.5%

[235 + Pages Report] According to a market research study published by The Brainy Insights, the demand analysis of Global…

Drug Delivery Devices Market revenue to hit USD 541.5 Billion by 2035, says Research Nester

Leading drug delivery devices market players include Antares Pharma, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis International AG, Johnson…

Oncology Active Pharmaceutical Ingredient (API) Market revenue to reach USD 7 Billion by 2035, says Research Nester

Leading Oncology Active Pharmaceutical Ingredient (API) Market players include Sanofi, AbbVie Inc., Merck & Co. Inc., Pfizer Inc., Abbott Laboratories,…

Specialty Generics Market to Reach USD 184.8 Billion by 2032; Increasing Capacity for Walking & Physical Activities to Propel Growth, says The Brainy Insights

Global specialty generics market size from USD 70.0 billion in 2022 to USD 184.8 billion, growing at a CAGR of…

TEVA Pharmaceutical: Neues Kursziel

Charlotte (www.aktiencheck.de) - Rating-Update: Jason Gerberry, Analyst von BofA Securities, wiederholt das Rating "buy" für die Aktie von TEVA Pharmaceutical Industries…

Form 8-K TEVA PHARMACEUTICAL INDU For: Aug 21

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5…

Teva Pharma lands US$225m fine for price-fixing

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

BofA sees Teva paying $1.5B total to settle price-fixing litigation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TEVA to Pay $250 Million to Settle Price-Fixing Charges

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5…

Teva Pharma lands US$225 million fine for price-fixing

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Teva Agrees to Pay $225 Million to Settle U.S. Price-Fixing Charges

The generic drugmakers U.S. unit also must sell the drug line for cholesterol treatment pravastatin....…

Teva to pay $225M to settle cholesterol drug price-fixing charges

The generic drug maker Teva Pharmaceuticals agreed Monday to pay $225 million to settle price-fixing charges related to sales of…

Teva Pharmaceuticals, Glenmark Pharmaceuticals Settle Price-Fixing Charges

PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals and Glenmark Pharmaceuticals have reached a settlement with the U.S. Department of Justice over…

Teva settles DOJ price-fixing case for $225M, plus product divestiture

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

DOJ orders Teva and Glenmark to pay millions in fines in drug price fixing settlment

CNBC's Bertha Coombs joins 'Closing Bell Overtime' with breaking news on the DOJ's antitrust agreement involving Teva and Glenmark....…

UPDATE 1-Teva to pay $225 mln to settle price-fixing charges

...(Adds details in paragraph 2-4) Aug 21 (Reuters) - Teva......…

Teva Pharmaceuticals agrees to pay $225 million fine to settle price-fixing charges

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. TEVA, said Monday that it has reached an agreement with…

Teva, Glenmark to Pay $275 Million to DOJ for Drug Price-Fixing

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Teva Pharmaceuticals to pay $225 mln to settle price-fixing charges

...Aug 21 (Reuters) - Teva Pharmaceuticals will pay a fine of $225......…

Teva Pharmaceuticals to pay $225 million to settle price-fixing charges

...(Reuters) - Teva Pharmaceuticals will pay a fine of $225 million......…

Teva to pay $225 million in fines and divest generic drug to resolve price-fixing charges

Its the latest resolution in a string of cases related to price-fixing, referring to competitors banding together to artificially set…

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide…

Teva agrees to pay $126 million to US hospitals over opioids

...By Brendan Pierson (Reuters) - Teva Pharmaceutical Industries Ltd......…

Teva agrees to pay $126 mln to US hospitals over opioids

...By Brendan Pierson Aug 3 (Reuters) - Teva Pharmaceutical Industries......…

Insiderhandel: See "Remarks" verkauft Aktien von Teva Pharma Industries im Wert von 437.690$

Hughes, Eric A. - Vorstand - Tag der Transaktion: 2023-08-01...…

UPDATE 1-Teva CEO says not too late to launch Humira biosimilar in 2024

... (Reuters) - Teva Pharmaceutical Industries will still pursue launching...," Francis told Reuters after Teva issued second-quarter results. "Its always......…

Teva CEO sees no value now in separating brands, generics businesses

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Teva Pharm CEO: Not too late to launch Humira biosimilar in 2024

...JERUSALEM (Reuters) - Teva Pharmaceutical Industries will still... this year. But I still see it as…

Teva Pharmaceutical Industries (TEVA) Q2 2023 Earnings Call Transcript

TEVA earnings call for the period ending June 30, 2023....…

Teva Pharmaceutical Shares Jump on Outlook Raise, 2Q Results

Teva Pharmaceutical Shares Jump on Outlook Raise, 2Q Results...…